Intravenous Infusion Pump Market Analysis

Intravenous Infusion Pump Market Analysis

Intravenous infusion pump market value from the syringe product segment is set to reach over USD 3 billion by 2032, owing to the product’s use as an excellent medicine delivery method for palliative care. Motor-driven syringe pumps with built-in software are gaining widespread adoption in hospitals, clinics, and other medical settings. Apart from ensuring a consistent therapeutic drug administration, this lightweight device allows for mobility. Furthermore, the high comfort, drug delivery in controlled amounts, and other attributes will boost syringe pump sales.
 

Intravenous infusion pump market size from the gastroenterology segment will cross USD 2.5 billion by 2032. This is considering the product’s effectiveness in ulcerative colitis, Crohn’s disease, and other digestive disorder treatment. According to UT Southwestern researchers, patients with inflammatory bowel disease enrolled in financial assistance programs are less likely to undergo surgery. This delivery of financial support for IBD treatment will escalate the usage of IV infusion pumps to deliver medications when oral medications are intolerant for digestive disease patients, eliminating side effects.
 

North America held a 36% share of the intravenous infusion pump market in 2022. The strong presence of Becton, Dickinson and Company, Baxter International Inc., and other IV pump developers is among the major growth drivers. The prevalence of bleeding disorders including hemophilia is also increasing, especially among men. Furthermore, chronic diseases have become the leading causes of death and disability. The high disease incidence will boost the rate of hospitalization and consequently accelerate intravenous infusion pump procedures across the region.